Literature DB >> 12559785

Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era.

Caroline Trotter1, Ray Borrow, Nick Andrews, Elizabeth Miller.   

Abstract

Sera from an age-stratified sample of 1689 individuals, submitted to the PHLS Seroepidemiology Unit between 1996 and 1999 were tested for serum bactericidal antibodies to serogroup C meningococci. Titres decreased during infancy, presumably as maternal antibody waned, and increased in older teenagers, the peak age of meningococcal carriage. The prevalence of antibody titres greater than or equal to 8 was highest in adults, with an average of 25% of adults 25 years old or above with titres above this putative protective level. In the absence of vaccination, antibody may be generated from periods of carriage of serogroup C meningococci, from other meningococcal strains sharing non-capsular antigens, and other cross-reactive organisms. The inverse relationship between disease incidence and the prevalence of 'protective' antibody titres as described by Goldschneider et al. appears more consistent with a titre of > or =8 rather than > or =128, although the proportions 'protected' are much lower here than in Goldschneider's study. This study provides baseline antibody levels which will facilitate the evaluation of the meningococcal serogroup C conjugate vaccination programme. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559785     DOI: 10.1016/s0264-410x(02)00630-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.

Authors:  David A Ishola; Ray Borrow; Helen Findlow; Jamie Findlow; Caroline Trotter; Mary E Ramsay
Journal:  Clin Vaccine Immunol       Date:  2012-05-30

2.  Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.

Authors:  Ray Borrow; Ingeborg S Aaberge; George F Santos; T Lynn Eudey; Philipp Oster; Anne Glennie; Jamie Findlow; E Arne Høiby; Einar Rosenqvist; Paul Balmer; Diana Martin
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

3.  Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Authors:  Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

4.  Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Authors:  George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

5.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

Review 6.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Authors:  Caroline Trotter; Jamie Findlow; Paul Balmer; Ann Holland; Rita Barchha; Nick Hamer; Nick Andrews; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

9.  Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?

Authors:  Richarda M de Voer; Fiona R M van der Klis; Laetitia E M Niers; Ger T Rijkers; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

10.  Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.

Authors:  Ray Borrow; David Goldblatt; Adam Finn; Joanna Southern; Lindsey Ashton; Nick Andrews; Gouri Lal; Christine Riley; Rukhsana Rahim; Keith Cartwright; Geraldine Allan; Elizabeth Miller
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.